Gallstone pancreatitis in a fifteen-year-old girl.

E. Albu,Amok Buiumsohn,P. Rosario,P. Gerst

DOI: https://doi.org/10.1097/00005176-199011000-00021

1990-11-01

Abstract:

What problem does this paper attempt to address?

Effects of Simvastatin on Cardiac Performance and Expression of Sarco-Plasmic Reticular Calcium Regulatory Proteins in Rat Heart

Xia Zheng,Shen-jiang Hu

DOI: https://doi.org/10.1111/j.1745-7254.2005.00105.x

IF: 7.169

2005-01-01

Acta Pharmacologica Sinica

Abstract:AbstractAim:To investigate the effect of simvastatin on the cardiac contractile function and the alteration of gene and protein expression of the sarcoplasmic calcium regulatory proteins, including sarcoplasmic reticulum Ca2+-ATPase (SERCA), phospholamban (PLB), and ryanodine receptor 2 (RyR2) in rat hearts.Methods:Langendorff-perfused rat hearts were subjected to 60-min perfusion with different concentrations of simvastatin (1, 3, 10, 30, or 100 μmol/L), and the parameters of cardiac function such as left ventricular developed pressure (LVDP), +dp/dtmax, and -dp/dtmax were determined. The cultured neonatal rat ventricular cardiomyocytes were incubated with simvastatin (1, 3, 10, 30, and 100 μmol/L) for 1 h or 24 h. The levels of SERCA, PLB, and RyR2 expression were measured by reverse transcription-polymerase chain reaction and Western blot. Cytotoxic effect of simvastatin on ventricular cardiomyocytes was assessed by the MTT colorimetric assay.Results:LVDP, +dp/dtmax, and -dp/dtmax of hearts were increased significantly after treatment with simvastatin 3, 10, and 30 μmol/L. In simvastatin-treated isolated hearts, the levels of mRNA expression of SERCA and RyR2 were elevated compared with the control (P<0.05), while the mRNA expression of PLB did not change. After the cultured neonatal rat ventricular cardiomyocytes were incubated with 3, 10, 30, and 100 μmol/L simvastatin for 1 h, SERCA and RyR2 mRNA expressions of cardiomyocytes rose, but there was no alteration in protein expressions. However, with the elongation of simvastatin treatment to 24 h, the protein expression of SERCA and RyR2 were also elevated. Additionally, simvastatin (1-30 μmol/L) had no influence on cell viability of cultured cardiac myocytes, but simvastatin 100 μmol/L inhibited the cell viability.Conclusion:Simvastatin improved cardiac performance accompanied by the elevation of SERCA and RyR2 gene and protein expression.
Apoptosis induced by simvastatin in rat vascular smooth muscle cell through Ca2+-calpain and caspase-3 dependent pathway.

Gang Cheng,Jiang Shan,Geng Xu,Jinyu Huang,Ji Ma,Shuqin Ying,Lijun Zhu

DOI: https://doi.org/10.1016/S1043-6618(03)00245-7

IF: 10.334

2003-01-01

Pharmacological Research

Abstract:Several studies have shown that simvastatin induces apoptosis in a variety of cell lines including vascular smooth muscle cells (VSMCs), but the exactly mechanisms involved in it is not very clear. The aim of this study was to investigate the mechanisms and signal pathways involved in apoptosis induced by simvastatin. When exposed to 30 microM simvastatin, [Ca2+]i in VSMCs increased with time and reached to 336 +/- 52 nM at 6 h, more than four-fold of control (P<0.01, n=5). Verapamil (80 microM), a membrane voltage-dependent Ca2+ channel blocker, attenuated simvastatin-induced augmentation of free calcium concentration from 336 +/- 52 nM to 144 +/- 34 nM (P<0.01). After being exposed to 30 microM simvastatin for 8 h, calpain activity markedly increased (P<0.05, n=4) and reached to more than three-fold of control at 12 h (P<0.01). Caspase-3 was also activated by simvastatin after 12 h. Verapamil and PD150606, a cell-permeable selective calpain inhibitor, significantly inhibited simvastatin-induced augmentation of calpain activity and blocked caspase-3 activation, respectively. Furthermore, 80 microM verapamil and 100 microM PD150606 decreased simvastatin-induced apoptosis rate from 24.2 +/- 1.7% to 7.9 +/- 0.6% (P<0.01, n=4) and 9.5 +/- 1.9% (P<0.01), respectively and also prevented simvastatin-induced DNA laddering. In conclusion, we indicated that simvastatin increases cytosolic free calcium concentration mainly through calcium influx from extracellular solution and then induces apoptosis by activating caspase-3 via calcium-dependent protease calpain.
Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-κB/p65 Expression

Lana Nežić,Ljiljana Amidžić,Ranko Škrbić,Radoslav Gajanin,Eugenie Nepovimova,Martin Vališ,Kamil Kuča,Vesna Jaćević

DOI: https://doi.org/10.3389/fphar.2019.00054

IF: 5.6

2019-02-15

Frontiers in Pharmacology

Abstract:Endotoxemia is associated by dysregulated apoptosis of immune and non-immune cells. We investigated whether simvastatin has anti-apoptotic effects, and induces hepatocytes and lymphocytes survival signaling in endotoxin-induced liver and spleen injuries. Wistar rats were divided into the groups pretreated with simvastatin (20 or 40 mg/kg, orally) prior to a non-lethal dose of lipopolysaccharide (LPS), the LPS group, and the control. The severity of tissue inflammatory injuries was expressed as hepatic damage scores (HDS) and spleen damage scores (SDS), respectively. The apoptotic cell was detected by TUNEL (Terminal deoxynucleotidyl transferase dUTP Nick End Labeling) and immunohistochemical staining (expression of cleaved caspase-3, and anti-apoptotic Bcl-xL, survivin and NF-κB/p65). Simvastatin dose-dependently abolished HDS and SDS induced by LPS (p < 0.01), respectively. Simvastatin 40 mg/kg significantly decreased apoptotic index and caspase-3 cleavage in hepatocytes and lymphocytes (p < 0.01 vs. LPS group, respectively), while Bcl-XL markedly increased accordingly with simvastatin doses. In the simvastatin, groups were determined markedly increased cytoplasmic expression of survivin associated with nuclear positivity of NF-κB, in both hepatocytes and lymphocytes (p < 0.01 vs. LPS group). Cell-protective effects of simvastatin against LPS seemed to be mediated by up-regulation of survivin, which leads to reduced caspase-3 activation and inhibition of hepatocytes and lymphocytes apoptosis.

pharmacology & pharmacy
Effect of Simvastatin on the Proliferation and Migration of Vascular Smooth Muscle Cells

ZHANG Li-Li,DAI Qiu-Yan

2008-01-01

Abstract:Aim To investigate the effect of simvastatin on the proliferation and migration of vascular smooth muscle cells and the expression of vascular endothelial growth factor mRNA. Methods The atherosclerotic vessel injured model was established and male Sprague-Dawley rats were divided into four groups randomly: normal control group, atherosclerotic injured group, low dose simvastatin group and high dose simvastatin group. The rats were put to death after 4 weeks. The serum lipid and the ratio of intima/ (intima + media) of thoracic aorta and left common carotid artery were detected, the expression of vascular endothelial growth factor on blood vessel was determined by immunohistochemistory and RT-PCR method. Results Simvastatin didn’t show biphasic effect on the proliferation and migration of vascular smooth muscle cells. Low dose simvastatin didn’t promote the proliferation and migration of vascular smooth muscle cells, while high dose simvastatin showed inhibition effect on the proliferation and migration of vascular smooth muscle cells, which was independent on lipid decreased. Simvastatin could diminish the vascular endothelial growth factor mRNA expression of vascular smooth muscle cells. Moreover, high dose simvastatin could significantly decrease the vascular endothelial growth factor mRNA expression. Conclusions Simvastatin might have inhibitive effect on vascular smooth muscle cells by decreasing the expression of vascular endothelial growth factor in vascular smooth muscle cells.
Effects of simvastatin on apolipoprotein M in vivo and in vitro

Xiaoying Zhang,Shubing Mao,Guanghua Luo,Jiang Wei,Maria Berggren-Söderlund,Peter Nilsson-Ehle,Ning Xu

DOI: https://doi.org/10.1186/1476-511X-10-112

2011-07-05

Abstract:Objective: To investigate effects of lipid lowering drug, simvastatin, on apolipoprotein M expression in the hyperlipidemic mice and in hepatic cell line, HepG2 cells. Methods: Swiss male mice were randomly divided into the high fat group and control group, and were intragastrically fed with 0.9% saline (control group) or lipid emulsion (high fat group) at the daily dosage of 15 ml/kg body weight, respectively. After 8 weeks feeding, the hyperlipidemic model was successfully induced and these hyperlipidemic mice were then randomly divided into three experimental groups: vehicle control group, high-dose simvastatin-treated group (100 mg/kg body weight), and low-dose simvastatin-treated group (10 mg/kg body weight). Mice were dosed daily for 6 weeks of simvastatin before mice were sacrificed for determining serum lipid profile and apoM protein levels that was determined by using dot blotting analysis. Effects of simvastatin on apoM mRNA expression in the HepG2 cells were determined by real-time RT-PCR. Results: Comparing to high fat model mice without simvastatin treatment, 100 mg/kg simvastatin could significantly increase serum total cholesterol (P < 0.05). Serum apoM levels, in all mice, were significantly lower in the mice at the age of 26 weeks than the mice at 12 weeks old (P < 0.05), which indicated that serum apoM levels were significantly correlated to the mice age. It demonstrated also that treatment of simvastatin did not influence serum apoM levels in these mouse model, although serum apoM levels were increased by about 13% in the 10 mg/kg simvastatin group than in the vehicle control group without simvastatin. In HepG2 cell cultures, simvastatin could significantly decrease apoM mRNA levels with dose- and time-dependent manners. At 10 μM simvastatin treatment, apoM mRNA decreased by 52% compared to the controls. Conclusion: The present study suggested that simvastatin, in vivo, had no effect on apoM levels in the hyperlipidemic mouse model. ApoM serum levels in mice were significantly correlated to the animal's age, whereas in cell cultures simvastatin does inhibit apoM expression in the HepG2 cells. The mechanism behind it is not known yet.
Apoptosis Induced by Simvastatin in Rat Vascular Smooth Muscle Cells Through Calpain and Caspase-3-dependent Pathways

程刚,徐耕,单江,黄进宇,周华

DOI: https://doi.org/10.3321/j.issn:1000-4718.2003.09.010

2003-01-01

Abstract:AIM: Hydroxymethylglutaryl CoA (HMG-CoA) reductase inhibitors, such as simvastatin, have been shown to reduce atherosclerotic cardiovascular morbidity and mortality by mechanisms unrelated to its lipid-lowering effect. Several studies have shown that simvastatin induces apoptosis in a varieties of cell lines including vascular smooth muscle cells (VSMC). The aim of this study was to investigate the signal pathways involved in apoptosis induced by simvastatin. METHODS: Cultured VSMC were treated with simvastatin. Calpain activity was determined by measuring Ca 2+ ionophore-specific calpain substrate (suc-LLVY-AMC), caspase-3 activation was detected by Western blot, and apoptotic changes were distinguished by annexin Ⅴ binding and DNA laddering. RESULTS: After incubated with 30 μmol/L simvastatin for 8 h, calpain activity had a marked increase ( P 0 05, n= 4) and reached to more than 3-fold of control at 12 h ( P 0 01) Caspase-3 also activated by simvastatin after 12 h PD150606, a cell-permeable selective calpain inhibitor, decreased simvastatin-induced apoptosis rate from 24 2%±1 7% to 9 5%±1 9% ( P 0 01) and also prevented simvastatin-induced DNA laddering. Furthermore, 100 μmol/L PD150606 efficiently inhibited simvastatin-induced caspase-3 activation. CONCLUSION:Simvastatin induces apoptosis by activating caspase-3 via calcium-dependent protease calpain.
Effects of long-time simvastatin-treated on bile acids homeostasis and relative gene expressions in hypercholesterolemia mice

Yu-qi HE,Yi-mei DU,Lei LING,Fei-fei MA,Chun-yuan ZHU,Rui-jie MAO,Xu-mei ZHOU,Li YANG,Zheng-tao WANG,Yu-he WANG,Yan-liu LU

DOI: https://doi.org/10.14109/j.cnki.xyylc.2017.09.011

2017-01-01

Abstract:AIM To investigate the role of simvastatin on bile acids regulation in high fat diet induced hypercholesterolemia mice.METHODS Three experimental groups were set up including normal diet group,high fat diet group,and simvastatin (20 mg·kg-1.d-1) group.Mice were feed with high fat diet for 16 weeks to establish the hypercholesterolemia model.Meanwhile,the normal diet group mice were feed with normal diet.Simvastatin were treated after week 16 for 22 weeks.Mice serum was collected for total cholesterol (TC),low density lipoprotein cholesterol (LDL-C),aspartate transaminase (AST) and alanine transaminase (ALT)assays.Mice livers were used for HE staining and mRNA expression analysis of genes involved in bile acids regulation.Hepatic bile acids assay was done by using LC-MS technology.RESULTS Simvastatin reduced the serum TC and LDL-C,showing the expected role on hypercholesterolemia treatment (P ＜ 0.05);however,accompanied by the abnormally induced ALT levels.Simvastatin attenuated repressed gene expression of Cyp 7al induced by high fat diet (P ＜ 0.05).In addition,simvastatin also induced the mRNA level of Cyp7al regulators in livers such as Fxr,Fgf15,Jnk1/2 and Erk1/2 (P ＜ 0.05).In particular,simvastatin also regulated bile acids regulators in small intestines such as Fgf1S.LC-MS analysis showed that most bile acids in liver tissues were significantly changed by simvastatin.CONCLUSION Simvastatin significantly changes expression levels of genes involved in bile acids homeostasis regulation.
Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity

Young-Eun Cho,Pyong-Gon Moon,Jeong-Eun Lee,Thoudam S K Singh,Wonku Kang,Hyun-Chul Lee,Myung-Hoon Lee,Sang-Hyun Kim,Moon-Chang Baek

DOI: https://doi.org/10.1002/pmic.201200368

PROTEOMICS

Abstract:Hepatocytes are used widely as a cell model for investigation of xenobiotic metabolism and the toxic mechanism of drugs. Simvastatin is the first statin drug used extensively in clinical practice for control of elevated cholesterol or hypercholesterolemia. However, it has also been reported to cause adverse effects in liver due to cellular damage. In this study, for proteomic and transcriptomic analysis, rat primary hepatocytes were exposed to simvastatin at IC20 concentration for 24 h. Among a total of 607 differentially expressed proteins, 61 upregulated and 29 downregulated proteins have been identified in the simvastatin-treated group. At the mRNA level, results of transcriptomic analysis revealed 206 upregulated and 41 downregulated genes in the simvastatin-treated group. Based on results of transcriptomic and proteomic analysis, NRF2-mediated oxidative stress response, xenobiotics by metabolism of cytochrome P450, fatty acid metabolism, bile metabolism, and urea cycle and inflammation metabolism pathways were focused using IPA software. Genes (FASN, UGT2B, ALDH1A1, CYP1A2, GSTA2, HAP90, IL-6, IL-1, FABP4, and ABC11) and proteins (FASN, CYP2D1, UG2TB, ALDH1A1, GSTA2, HSP90, FABP4, and ABCB11) related to several important pathways were confirmed by real-time PCR andWestern blot analysis, respectively. This study will provide new insight into the potential toxic pathways induced by simvastatin.
Simvastatin inhibit proliferation in vascular smooth muscle cells in association with induction of PTEN and p27

单江,程刚,傅国胜,翁少翔

DOI: https://doi.org/10.3760/j:issn:0253-3758.2002.10.016

2002-01-01

Abstract:Objective To observe the role of simvastatin on the proliferation of vascular smooth muscle cells(VSMC) and the effect of simvastatin on the expression of p21, p27, PTEN and c myc To investigate if simvastatin increased p27 expression through induction of PTEN gene expression and whether mevalonate, substrate of the HMG COA reductase, was invovled in simvastatin induced PTEN and p27 expression Methods The DNA synthesis was determined by TdR incorporation, cell cycle was examined with flow cytometry, the protein level of p21, p27, PTEN and c myc were measured by Western blot method The sense and antisense oligodeo xynucleotides(ODNs) for PTEN were designed and synthesized They were individually delivered to the cultured VSMC by lipofectin mediated gene transfer method After liposomal transfecting, cells were exposed to 5 μmol/Lsimvastatin for 48h and then harvested in lysis buffer The efficiency of transfer ODNs into VSMC was examined by Western blot method Results (1) simvastatin inhibited TdR incorporation in a dose dependent manner (1 μmol/L 10 μmol/L) (2) Flow cytometric DNA analysis revealed that simvastatin induced significantly enhancement of G 0/G 1 phase and attenuation of S phase VSMC compared with those of control group (3)simvastatin increased protein level of PTEN and p27 but did not have effect on p21 and c myc (4) PTEN antisense ODNs efficiently attenuated the expression of PTEN protein but had no effect on p27 protein level (5) 200 μmol/L mevalonate prevented simvastatin induced p27 an PTEN protein expression significantly Conclusion simvastatin could inhibit proliferation of VSMC and retarded cell cycle in G 0/G 1 phase by regulating expression of two G 1 /S transfer related genes PTEN and p27 independently Up regulation of p27 and PTEN by simvastatin might be mediated by its inhibition on the mevalonate pathway
The effects of simvastatin-loaded nanoliposomes on human multilineage liver fibrosis microtissue

Shima Parsa,Maryam Dousti,Nasim Mohammadi,Mozhgan Abedanzadeh,Niloofar Dehdari Ebrahimi,Mahintaj Dara,Mahsa Sani,Muhammad Nekouee,Samira Sadat Abolmaali,Farnaz Sani,Negar Azarpira

DOI: https://doi.org/10.1111/jcmm.18529

Abstract:In this in vitro study, for the first time, we evaluate the effects of simvastatin-loaded liposome nanoparticles (SIM-LipoNPs) treatment on fibrosis-induced liver microtissues, as simvastatin (SIM) has shown potential benefits in the non-alcoholic fatty liver disease process. We developed multicellular liver microtissues composed of hepatic stellate cells, hepatoblastoma cells and human umbilical vein endothelial cells. The microtissues were supplemented with a combination of palmitic acid and oleic acid to develop fibrosis models. Subsequently, various groups of microtissues were exposed to SIM and SIM-LipoNPs at doses of 5 and 10 mg/mL. The effectiveness of the treatments was evaluated by analysing cell viability, production of reactive oxygen species (ROS) and nitric oxide (NO), the expression of Kruppel-like factor (KLF) 2, and pro-inflammatory cytokines (interleukin(IL)-1 α, IL-1 β, IL-6 and tumour necrosis factor-α), and the expression of collagen I. Our results indicated that SIM-LipoNPs application showed promising results. SIM-LipoNPs effectively amplified the SIM-klf2-NO pathway at a lower dosage compatible with a high dosage of free SIM, which also led to reduced oxidative stress by decreasing ROS levels. SIM-LipoNPs administration also resulted in a significant reduction in pro-inflammatory cytokines and Collagen I mRNA levels, as a marker of fibrosis. In conclusion, our study highlights the considerable therapeutic potential of using SIM-LipoNPs to prevent liver fibrosis progress, underscoring the remarkable properties of SIM-LipoNPs in activating the KLF2-NO pathway and anti-oxidative and anti-inflammatory response.
[Postoperative MRSA infections in digestive tract surgery].

K. Soeda,H. Kanno,K. Isono

1992-05-01

Abstract:MRSA strains were first isolated in 1981 and have increased markedly from 1985 in our surgical ward. One hundred and ninety four strains of MRSA were isolated and 81 cases developed critical infections which were associated with enterocolitis, pneumonia and sepsis. There were many cases in esophageal cancer patients. Bacteriological features of the MRSA strains clearly changed in 1985 from IV to II coagulase type, accompanied with high resistance for antibiotics. Our management against nosocomial infection for MRSA started from April 1988. The number of MRSA cases decreased in 1989, increased in 1990 and decreased again in 1991. We are confident that our management is effective and we will take further efforts to choose the most adequate antibiotics after surgery in our surgical ward.
Amelioration of Endotoxin-Induced Acute Lung Injury and Alveolar Epithelial Cells Apoptosis by Simvastatin Is Associated with Up-Regulation of Survivin/NF-kB/p65 Pathway

Lana Nežić,Ljiljana Amidžić,Ranko Škrbić,Radoslav Gajanin,Danijela Mandić,Jelena Dumanović,Zoran Milovanović,Vesna Jaćević

DOI: https://doi.org/10.3390/ijms23052596

IF: 5.6

2022-02-26

International Journal of Molecular Sciences

Abstract:Disruption of the alveolar–endothelial barrier caused by inflammation leads to the progression of septic acute lung injury (ALI). In the present study, we investigated the beneficial effects of simvastatin on the endotoxin lipopolysaccharide (LPS)-induced ALI and its related mechanisms. A model of ALI was induced within experimental sepsis developed by intraperitoneal injection of a single non-lethal LPS dose after short-term simvastatin pretreatment (10–40 mg/kg orally). The severity of the lung tissue inflammatory injury was expressed as pulmonary damage scores (PDS). Alveolar epithelial cell apoptosis was confirmed by TUNEL assay (DNA fragmentation) and expressed as an apoptotic index (AI), and immunohistochemically for cleaved caspase-3, cytochrome C, and anti-apoptotic Bcl-xL, an inhibitor of apoptosis, survivin, and transcriptional factor, NF-kB/p65. Severe inflammatory injury of pulmonary parenchyma (PDS 3.33 ± 0.48) was developed after the LPS challenge, whereas simvastatin significantly and dose-dependently protected lung histology after LPS (p < 0.01). Simvastatin in a dose of 40 mg/kg showed the most significant effects in amelioration alveolar epithelial cells apoptosis, demonstrating this as a marked decrease of AI (p < 0.01 vs. LPS), cytochrome C, and cleaved caspase-3 expression. Furthermore, simvastatin significantly enhanced the expression of Bcl-xL and survivin. Finally, the expression of survivin and its regulator NF-kB/p65 in the alveolar epithelium was in strong positive correlation across the groups. Simvastatin could play a protective role against LPS-induced ALI and apoptosis of the alveolar–endothelial barrier. Taken together, these effects were seemingly mediated by inhibition of caspase 3 and cytochrome C, a finding that might be associated with the up-regulation of cell-survival survivin/NF-kB/p65 pathway and Bcl-xL.
Effect of simvastatin on bovine intramuscular and subcutaneous adipocytes proliferation and gene expression in vitro

Qing Jin,Chen Wei,Hong-Bo Zhao,Xiu-Wen Tan,Fa-Chun Wan,Gui-Fen Liu

DOI: https://doi.org/10.1080/10495398.2019.1607749

Abstract:Simvastatin (SIM) is a widely used anticholesterolemic drug that blocks the biosynthesis of cholesterol. However, SIM also has pleiotropic effects on 3-hydroxy-3-methyglutary-CoA reductase (HMGR), cholesteryl ester transfer protein (CETP), and lipoprotein lipase (LPL), which are important genes in the cholesterol biosynthesis and transport processes. We investigated the effects of different concentrations of SIM on the mRNA expression of these genes in bovine intramuscular and subcutaneous adipocytes from the longissimus dorsi muscle and subcutaneous fat tissues of Luxi Yellow cattle. The results showed that SIM treatment showed dose-dependent toxicity on normal adipose cells, but no effect on cell proliferation. SIM decreased HMGR expression in a dose-dependent manner but showed no significant effect on CETP and LPL expression. Thus, SIM may lower the cholesterol content by decreasing the HMGR expression level, but CETP and LPL may be regulated through other mechanisms, which require further investigation.
Protective Effects of Simvastatin on Endotoxin-Induced Acute Kidney Injury through Activation of Tubular Epithelial Cells’ Survival and Hindering Cytochrome C-Mediated Apoptosis

Lana Nežić,Ranko Škrbić,Ljiljana Amidžić,Radoslav Gajanin,Zoran Milovanović,Eugenie Nepovimova,Kamil Kuča,Vesna Jaćević

DOI: https://doi.org/10.3390/ijms21197236

IF: 5.6

2020-09-30

International Journal of Molecular Sciences

Abstract:Increasing evidence suggests that apoptosis of tubular cells and renal inflammation mainly determine the outcome of sepsis-associated acute kidney injury (AKI). The study aim was to investigate the molecular mechanism involved in the renoprotective effects of simvastatin in endotoxin (lipopolysaccharide, LSP)-induced AKI. A sepsis model was established by intraperitoneal injection of a single non-lethal LPS dose after short-term simvastatin pretreatment. The severity of the inflammatory injury was expressed as renal damage scores (RDS). Apoptosis of tubular cells was detected by Terminal deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (TUNEL assay) (apoptotic DNA fragmentation, expressed as an apoptotic index, AI) and immunohistochemical staining for cleaved caspase-3, cytochrome C, and anti-apoptotic Bcl-xL and survivin. We found that endotoxin induced severe renal inflammatory injury (RDS = 3.58 ± 0.50), whereas simvastatin dose-dependently prevented structural changes induced by LPS. Furthermore, simvastatin 40 mg/kg most profoundly attenuated tubular apoptosis, determined as a decrease of cytochrome C, caspase-3 expression, and AIs (p < 0.01 vs. LPS). Conversely, simvastatin induced a significant increase of Bcl-XL and survivin, both in the strong inverse correlations with cleaved caspase-3 and cytochrome C. Our study indicates that simvastatin has cytoprotective effects against LPS-induced tubular apoptosis, seemingly mediated by upregulation of cell-survival molecules, such as Bcl-XL and survivin, and inhibition of the mitochondrial cytochrome C and downstream caspase-3 activation.

biochemistry & molecular biology,chemistry, multidisciplinary
The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet

Qing Zhang,Xiaoyun Fan,Rui Ye,Yuzhong Hu,Tingting Zheng,Rui Shi,Wenjian Cheng,Xucong Lv,Lijiao Chen,Peng Liang

DOI: https://doi.org/10.3389/fphar.2020.00522

IF: 5.6

2020-01-01

Frontiers in Pharmacology

Abstract:The objective of this study was to investigate the effects of simvastatin (SIM) on lipid metabolism disorders and gut microbiota in high-fat diet-induced hyperlipidemic rats. The obtained results revealed that feeding rats with SIM (20 mg/kg/day) significantly decreased serum lipid level and inhibited hepatic lipid accumulation and steatosis. Histological analysis further indicated that SIM reduced lipid deposition in adipocytes and hepatocytes in comparison with that of the HFD group. The underlying mechanisms of SIM administration against HFD-induced hyperlipidemia were also studied by UPLC-Q-TOF/MS-based liver metabonomics coupled with pathway analysis. Metabolic pathway enrichment analysis of liver metabolites with significant difference in abundance indicated that fatty acids metabolism and amino acid metabolism were the main metabolic pathways altered by SIM administration. Meanwhile, operational taxonomic units (OTUs) analysis revealed that oral administration of SIM altered the composition of gut microbiota, includingRuminococcaceae(OTU960) andLactobacillus(OTU152), and so on. Furthermore, SIM treatment also regulated the mRNA levels of the genes involved in lipid and cholesterol metabolism. Immunohistochemistry (IHC) analysis of the liver-related proteins (CD36, CYP7A1 and SREBP-1C) showed that oral administration of SIM could regulate the levels of the protein expression related to hepatic lipid metabolism.
Simvastatin Protects Cardiomyocytes Against Endotoxin-induced Apoptosis and Up-regulates Survivin/NF-κB/p65 Expression

Lana Nežić,Ranko Škrbić,Ljiljana Amidžić,Radoslav Gajanin,Kamil Kuča,Vesna Jaćević

DOI: https://doi.org/10.1038/s41598-018-32376-4

IF: 4.6

2018-10-02

Scientific Reports

Abstract:This study is aimed to investigate whether simvastatin induces cardiomyocytes survival signaling in endotoxin (lipopolysaccharide, LSP)-induced myocardial injury, and if so, further to determine a role of survivin in simvastatin-anti-apoptotic effect. Wistar rats were pretreated with simvastatin (10–40 mg/kg po) before a single non-lethal dose of LPS. In myocardial tissue, LPS induced structural disorganization of myofibrils with significant inflammatory infiltrate (cardiac damage score, CDS = 3.87 ± 0.51, p < 0.05), whereas simvastatin dose-dependently abolished structural changes induced by LPS (p < 0.01). Simvastatin in 20 mg/kg and 40 mg/kg pretreatment, dose dependently, attenuated myocardial apoptosis determined as apoptotic index (28.8 ± 4.5% and 18.9 ± 3.5, p < 0.05), decreased cleaved caspase-3 expression (32.1 ± 5.8%, p < 0.01), along with significant Bcl-xL expression in the simvastatin groups (p < 0.01). Interestingly, in the simvastatin groups were determined significantly increased expression of survivin (p < 0.01), but in negative correlation with cleaved caspase-3 and apoptotic indices (p < 0.01). Simvastatin has a cardioprotective effects against LPS induced apoptosis. The effect may be mediated by up-regulation of survivin via activation of NF-κB, which leads to reduced activation of caspase-3 and consequent apoptosis of cardiomyocytes in experimental sepsis.

multidisciplinary sciences
Simvastatin Inhibits the Formation of NETs by the Mac-1 Pathway to Reduce Hepatic Ischemia-Reperfusion Injury under High-Fat Conditions

Shikai Wang,Zhipeng Li,Yunxiang Chang,Kai Dong,Di He,Xinsheng Cheng

DOI: https://doi.org/10.24976/Discov.Med.202436187.158

Abstract:Background: Hyperlipidemia is one of the main causes of aggravated hepatic ischemia-reperfusion injury (IRI). Simvastatin (SIM), a lipid-lowering drug, has been shown to effectively alleviate IRI caused by hyperlipidemia. However, the regulatory mechanism by which SIM alleviates hyperlipidemia-induced hepatic IRI is still not clear. This study aims to explore the potential mechanisms of SIM in inhibiting hyperlipidemia-induced hepatic IRI, providing new therapeutic strategies for the alleviation of hepatic IRI. Methods: An animal model of hyperlipidemia was induced by feeding mice a high-fat diet for 8 weeks. Subsequently, a hepatic IRI animal model of hyperlipidemia was established by occluding the hepatic artery and portal vein for one hour, followed by reperfusion for 6 or 12 h. Enzyme linked immunosorbent assay, Western blotting, hematoxylin-eosin (H&E) staining, immunohistochemistry, immunofluorescence, and Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling assay, were used to evaluate liver injury, neutrophil extracellular traps (NETs) formation, and related molecular mechanisms. Results: Hepatic IRI was accelerated by hyperlipidemia, which enhanced the expression of oxidized low-density lipoprotein (oxLDL) and Macrophage-1antigen (Mac-1), leading to the promotion of NETs formation and apoptosis of liver cells. The administration of simvastatin reduced the levels of oxLDL and Mac-1, decreased the formation of NETs, and alleviated hepatic IRI induced by hyperlipidemia. Conclusions: Simvastatin reduced hyperlipidemia-induced hepatic IRI by inhibiting the formation of NETs through the regulation of the oxLDL/Mac-1 pathway.
A strong association of HLA-DR 3/4 heterozygotes with insulin-dependent diabetes among Chinese in Taiwan.

H. S. Huang,M. J. Huang,C. Huang,B. Huang,P. W. Wang,J. D. Lin

Abstract:
Influence of Simvastatin and Pravastatin on the Biophysical Properties of Model Lipid Bilayers and Plasma Membranes of Live Cells

Artu Ras Polita,Ru Ta Bagdonaitė,Arun Prabha Shivabalan,Gintaras Valinčius

DOI: https://doi.org/10.1021/acsbiomaterials.4c00911

2024-08-24

Abstract:Statins are among the most widely used drugs for the inhibition of cholesterol biosynthesis, prevention of cardiovascular diseases, and treatment of hypercholesterolemia. Additionally, statins also exhibit cholesterol-independent benefits in various diseases, including neuroprotective properties in Alzheimer's disease, anti-inflammatory effects in coronary artery disease, and antiproliferative activities in cancer, which likely result from the statins' interaction and alteration of lipid bilayers. However, the membrane-modulatory effects of statins and the mechanisms by which statins alter lipid bilayers remain poorly understood. In this work, we explore the membrane-modulating effects of statins on model lipid bilayers and live cells. Through the use of fluorescence lifetime imaging microscopy (FLIM) combined with viscosity-sensitive environmental probes, we demonstrate that hydrophobic, but not hydrophilic, statins are capable of changing the microviscosity and lipid order in model and live cell membranes. Furthermore, we show that hydrophobic simvastatin is capable of forming nanoscale cholesterol-rich domains and homogenizing the cholesterol concentrations in lipid bilayers. Our results provide a mechanistic framework for understanding the bimodal effects of simvastatin on the lipid order and the lateral organization of cholesterol in lipid bilayers. Finally, we demonstrate that simvastatin temporarily decreases the microviscosity of live cell plasma membranes, making them more permeable and increasing the level of intracellular chemotherapeutic drug accumulation.
Effect of Statin Lipophilicity on the Proliferation of Hepatocellular Carcinoma Cells

Goda Glebavičiūtė,Akshay Vijaya,Giulio Preta

DOI: https://doi.org/10.3390/biology13060455

2024-06-20

Biology

Abstract:The HMG-CoA reductase inhibitors, statins, are drugs used globally for lowering the level of cholesterol in the blood. Different clinical studies of statins in cancer patients have indicated a decrease in cancer mortality, particularly in patients using lipophilic statins compared to those on hydrophilic statins. In this paper, we selected two structurally different statins (simvastatin and pravastatin) with different lipophilicities and investigated their effects on the proliferation and apoptosis of hepatocellular carcinoma cells. Lipophilic simvastatin highly influences cancer cell growth and survival in a time- and concentration-dependent manner, while pravastatin, due to its hydrophilic structure and limited cellular uptake, showed minimal cytotoxic effects.

biology

Gallstone pancreatitis in a fifteen-year-old girl.

Effects of Simvastatin on Cardiac Performance and Expression of Sarco-Plasmic Reticular Calcium Regulatory Proteins in Rat Heart

Apoptosis induced by simvastatin in rat vascular smooth muscle cell through Ca2+-calpain and caspase-3 dependent pathway.

Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-κB/p65 Expression

Effect of Simvastatin on the Proliferation and Migration of Vascular Smooth Muscle Cells

Effects of simvastatin on apolipoprotein M in vivo and in vitro

Apoptosis Induced by Simvastatin in Rat Vascular Smooth Muscle Cells Through Calpain and Caspase-3-dependent Pathways

Effects of long-time simvastatin-treated on bile acids homeostasis and relative gene expressions in hypercholesterolemia mice

Integrative analysis of proteomic and transcriptomic data for identification of pathways related to simvastatin-induced hepatotoxicity

Simvastatin inhibit proliferation in vascular smooth muscle cells in association with induction of PTEN and p27

The effects of simvastatin-loaded nanoliposomes on human multilineage liver fibrosis microtissue

[Postoperative MRSA infections in digestive tract surgery].

Amelioration of Endotoxin-Induced Acute Lung Injury and Alveolar Epithelial Cells Apoptosis by Simvastatin Is Associated with Up-Regulation of Survivin/NF-kB/p65 Pathway

Effect of simvastatin on bovine intramuscular and subcutaneous adipocytes proliferation and gene expression in vitro

Protective Effects of Simvastatin on Endotoxin-Induced Acute Kidney Injury through Activation of Tubular Epithelial Cells’ Survival and Hindering Cytochrome C-Mediated Apoptosis

The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet

Simvastatin Protects Cardiomyocytes Against Endotoxin-induced Apoptosis and Up-regulates Survivin/NF-κB/p65 Expression

Simvastatin Inhibits the Formation of NETs by the Mac-1 Pathway to Reduce Hepatic Ischemia-Reperfusion Injury under High-Fat Conditions

A strong association of HLA-DR 3/4 heterozygotes with insulin-dependent diabetes among Chinese in Taiwan.

Influence of Simvastatin and Pravastatin on the Biophysical Properties of Model Lipid Bilayers and Plasma Membranes of Live Cells

Effect of Statin Lipophilicity on the Proliferation of Hepatocellular Carcinoma Cells